Compare Merck & Co., Inc. (MRK) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Roundhill NVDA WeeklyPay ETF — how do they compare? Merck & Co., Inc. trades at $133.42 (market cap $321.77B), while Roundhill NVDA WeeklyPay ETF trades at $38.32. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| MRK | NVDW | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $131.84 | $52.59 |
52-Week Low | $77.60 | $31.88 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
NVDW trades at $38.58, up 3.35% today with a bullish technical signal supported by moving averages. The stock shows strong momentum with key indicators suggesting mild overbought conditions. Recent dividend activity indicates consistent shareholder returns, though financial ratios remain undisclosed pending updated filings.
Outlook remains positive given technical strength and dividend consistency, but limited fundamental data requires caution. Key risks include dependency on underlying NVDA performance and payout volatility. Investors should await comprehensive financial disclosures for full valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
